BioPharma Dive October 12, 2021
An experimental “off-the-shelf” cell therapy for cancer helped eliminate or reduce disease in more than half of the lymphoma patients infused with higher doses in a clinical trial, a finding that the treatment’s owner, CRISPR Therapeutics, says can match up with similar, rival drugs that are more logistically complex.
The trial also showed the treatment so far hasn’t caused severe cases of a potentially deadly immune-related condition caused by cancer therapies that are made using a patient’s own cells. The results are likely to add fuel an ongoing debate over how effective off-the-shelf therapies — which rely on cells donated by healthy people — might be when compared to the patient-derived versions, such as Novartis’ Kymriah and Gilead’s Yescarta.
Those...
Today's Sponsors
Today's Sponsor